Bayer buys Perfuse in $2.4B deal for midphase eye disease prospect Read more →

CellCentric raises $220M series D to advance myeloma drug through registration, eyes potential IPO Read more →

After a decade of hype, Najat Khan is bringing Recursion back down to earth Read more →